Compare AU

Compare CURE vs. VBND

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Vanguard Global Aggregate Bond Index (Hedged) ETF (VBND). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

VBND

Popularity

Low

Low

Pearlers invested

83

124

Median incremental investment

$619.50

$1,025.69

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$2,455.14

Average age group

> 35

> 35


Key Summary

CURE

VBND

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

VBND.AX was created on 2017-10-10 by Vanguard. The fund's investment portfolio concentrates primarily on investment grade fixed income. Vanguard Global Aggregate Bond Index (Hedged) ETF seeks to track the return of the Bloomberg Barclays Global Aggregate Float-Adjusted and Scaled Index hedged into Australian dollars before taking into account fees, expenses and tax

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

United States Treasury Note/Bond 4.25 2024-12-31 (0.39 %)

United States Treasury Note/Bond 4.5 2024-11-30 (0.37 %)

Italy Buoni Poliennali Del Tesoro 3.4 2025-03-28 (0.33 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.2 %


Key Summary

CURE

VBND

Issuer

Global X

Vanguard

Tracking index

S&P Biotechnology Select Industry

Bloomberg Barclays Global Aggregate Float Adjusted Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.2 %

Price

$51.33

$42.33

Size

$36.301 million

$4.185 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

3.65 %

Market

ASX

ASX

First listed date

12/11/2018

12/10/2017

Purchase fee

$6.50

$6.50


Community Stats

CURE

VBND

Popularity

Low

Low

Pearlers invested

83

124

Median incremental investment

$619.50

$1,025.69

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$2,455.14

Average age group

> 35

> 35


Pros and Cons

CURE

VBND

Pros

  • Higher exposure to US market

  • Higher price growth

  • Higher distribution yield

  • Lower management fee

Cons

  • Higher management fee

  • Lower exposure to US market

  • Lower price growth

  • Lower distribution yield

CURE

VBND

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Higher distribution yield

Lower distribution yield

Home